CTSS and neoplasm: Since the cathepsin and galectins axis may fuel the vicious cycle of a pro-vasculogenic environment [134], cathepsin/galectin targeting prompted novel strategies combining anti-angiogenic therapy and immunotherapy, with the potential to tip the balance of the tumor microenvironment and improve treatment response [141,147,148,149].